Most patents on subcutaneous LHRH agonists have better performance status after years of initiating therapy, when compared to patients offered bilateral simple orchidectomy.

Time to re-evaluate.

More Emmanuel Ahuizechukwu Obiesie's questions See All
Similar questions and discussions